CW Advisors LLC Buys New Position in Edwards Lifesciences Corporation $EW

Key Points

• CW Advisors LLC made a new investment in Edwards Lifesciences Corporation, purchasing 6,359 shares valued at approximately $459,000 in the first quarter.
• Edwards Lifesciences reported an EPS of $0.67 for the last quarter, exceeding analyst expectations, with total quarterly revenue of $1.53 billion, reflecting an 11.9% year-over-year increase.
• Wall Street analysts have upgraded their ratings and price targets for Edwards Lifesciences, with an average price target of $85.90 and several analysts giving it a "buy" rating.

CW Advisors LLC purchased a new stake in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 6,359 shares of the medical research company's stock, valued at approximately $459,000.

Several other institutional investors also recently added to or reduced their stakes in EW. Brighton Jones LLC bought a new position in Edwards Lifesciences during the fourth quarter valued at about $266,000. Bank Pictet & Cie Europe AG grew its position in Edwards Lifesciences by 16.7% during the fourth quarter. Bank Pictet & Cie Europe AG now owns 10,231 shares of the medical research company's stock valued at $757,000 after buying an additional 1,463 shares during the period. Integrated Wealth Concepts LLC grew its position in Edwards Lifesciences by 23.4% during the fourth quarter. Integrated Wealth Concepts LLC now owns 9,790 shares of the medical research company's stock valued at $725,000 after buying an additional 1,856 shares during the period. Northern Trust Corp grew its position in Edwards Lifesciences by 21.8% during the fourth quarter. Northern Trust Corp now owns 6,505,227 shares of the medical research company's stock valued at $481,582,000 after buying an additional 1,165,845 shares during the period. Finally, AQR Capital Management LLC grew its position in Edwards Lifesciences by 43.5% during the fourth quarter. AQR Capital Management LLC now owns 208,889 shares of the medical research company's stock valued at $15,464,000 after buying an additional 63,313 shares during the period. Institutional investors own 79.46% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on EW. Royal Bank Of Canada increased their price target on shares of Edwards Lifesciences from $85.00 to $89.00 and gave the company an "outperform" rating in a research report on Friday, July 25th. Robert W. Baird boosted their price target on shares of Edwards Lifesciences from $78.00 to $79.00 and gave the company a "neutral" rating in a research report on Friday, July 25th. Barclays upped their price target on shares of Edwards Lifesciences from $90.00 to $95.00 and gave the company an "overweight" rating in a research note on Friday, July 25th. Citigroup restated a "buy" rating and set a $95.00 price target (up from $84.00) on shares of Edwards Lifesciences in a research note on Thursday, May 22nd. Finally, Evercore ISI upped their price target on shares of Edwards Lifesciences from $77.00 to $80.00 and gave the company an "in-line" rating in a research note on Friday, July 25th. Three equities research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $85.90.

Edwards Lifesciences Price Performance

Shares of Edwards Lifesciences stock traded up $0.40 on Tuesday, reaching $81.74. The stock had a trading volume of 902,119 shares, compared to its average volume of 4,472,022. Edwards Lifesciences Corporation has a 1 year low of $64.00 and a 1 year high of $83.00. The company has a market cap of $47.99 billion, a P/E ratio of 11.76, a price-to-earnings-growth ratio of 3.92 and a beta of 1.07. The company has a current ratio of 4.68, a quick ratio of 3.87 and a debt-to-equity ratio of 0.06. The business's 50 day moving average is $78.43 and its two-hundred day moving average is $75.05.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its quarterly earnings results on Thursday, July 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.62 by $0.05. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The firm had revenue of $1.53 billion for the quarter, compared to the consensus estimate of $1.49 billion. During the same period in the prior year, the firm posted $0.70 earnings per share. The company's revenue for the quarter was up 11.9% on a year-over-year basis. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. As a group, research analysts anticipate that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Insider Transactions at Edwards Lifesciences

In related news, VP Daniel J. Lippis sold 4,114 shares of the firm's stock in a transaction that occurred on Monday, July 28th. The shares were sold at an average price of $79.46, for a total value of $326,898.44. Following the sale, the vice president directly owned 22,002 shares of the company's stock, valued at $1,748,278.92. This trade represents a 15.75% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Larry L. Wood sold 8,950 shares of the firm's stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $78.06, for a total transaction of $698,637.00. Following the completion of the sale, the insider directly owned 206,900 shares in the company, valued at $16,150,614. This represents a 4.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 22,014 shares of company stock worth $1,698,844. Insiders own 0.34% of the company's stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.